Prevalence of Dual-Positivity for Both Hepatitis B e Antigen and Hepatitis B e Antibody Among Hospitalized Patients with Chronic Hepatitis B Virus Infection.
hepatitis B e antibody
hepatitis B e antigen
Journal
International journal of general medicine
ISSN: 1178-7074
Titre abrégé: Int J Gen Med
Pays: New Zealand
ID NLM: 101515487
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
07
2021
accepted:
25
08
2021
entrez:
24
9
2021
pubmed:
25
9
2021
medline:
25
9
2021
Statut:
epublish
Résumé
The detection of dual-positivity for both hepatitis B e antigen (HBeAg) and hepatitis B e antibody (anti-HBe) is not typically performed for patients with hepatitis B virus (HBV). This cross-sectional study was designed to figure out the prevalence of dual-positivity for both HBeAg and anti-HBe (DEP) among hospitalized patients with chronic hepatitis B virus infection (C-HBVI). Data from 2820 cases with C-HBVI from two centers in China were retrospectively analyzed. Univariate and multivariate logistic regression analyses were undertaken to identify the risk factors for liver fibrosis (LF) and acute-on-chronic liver failure (ACLF). There were 165 (5.9%), 688, and 1903 patients in DEP, HBeAg+/anti-HBe-, and HBeAg-/anti-HBe+ groups, respectively. The DEP patients' median age was 43.6 years old and 71.5% of them were male. They had higher levels of alanine transaminase, total bilirubin, and international normalized ratio. Furthermore, DEP cases had a higher proportion of liver cirrhosis, and it was associated with non-invasive testing of LF, including aspartate transaminase (AST)-to-platelet ratio index (APRI) >1.5 (odds ratio (OR) = 1.96, 95% confidence interval (CI): 1.27-3.03, DEP cases are at higher risks of LF and ACLF than other patients with HBV infection. A fast diagnosis and an active monitoring of liver diseases for DEP patients are extremely vital.
Identifiants
pubmed: 34557028
doi: 10.2147/IJGM.S328714
pii: 328714
pmc: PMC8454426
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5759-5770Informations de copyright
© 2021 Liu et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest.
Références
Hepatology. 2018 Dec;68(6):2325-2337
pubmed: 29790188
J Gastroenterol Hepatol. 2013 May;28(5):855-60
pubmed: 23278507
Hepatol Int. 2019 Jul;13(4):353-390
pubmed: 31172417
Hepatology. 2016 Jan;63(1):261-83
pubmed: 26566064
J Clin Virol. 2005 Dec;34 Suppl 1:S125-9
pubmed: 16461211
Int J Med Sci. 2006;3(1):14-20
pubmed: 16421626
J Gen Virol. 2000 Jan;81(Pt 1):75-83
pubmed: 10640544
Cell Immunol. 2012 Mar-Apr;276(1-2):35-41
pubmed: 22551558
Arch Dis Child. 1983 Jul;58(7):488-96
pubmed: 6870328
Blood Transfus. 2007 Nov;5(4):227-40
pubmed: 19204779
Genet Mol Res. 2017 Feb 23;16(1):
pubmed: 28252163
J Hepatol. 2009 Feb;50(2):273-80
pubmed: 19070921
Hepatology. 2018 Apr;67(4):1560-1599
pubmed: 29405329
Braz J Infect Dis. 2017 Sep - Oct;21(5):525-529
pubmed: 28606415
Zhonghua Gan Zang Bing Za Zhi. 2012 Mar;20(3):206-10
pubmed: 22475141
J Hepatol. 2003 Jan;38(1):98-103
pubmed: 12480566
Oncotarget. 2016 Mar 15;7(11):12525-36
pubmed: 26848866
Gastroenterology. 1983 Feb;84(2):216-9
pubmed: 6848402
J Viral Hepat. 2011 Sep;18(9):646-52
pubmed: 20636332
Dig Dis Sci. 2019 Sep;64(9):2563-2569
pubmed: 30835025
Bull World Health Organ. 2019 Mar 1;97(3):230-238
pubmed: 30992636
Medicine (Baltimore). 2017 May;96(19):e6835
pubmed: 28489767
Hepatology. 2003 Aug;38(2):518-26
pubmed: 12883497
Hepatology. 2006 Jun;43(6):1317-25
pubmed: 16729309
J Gastroenterol Hepatol. 2003 Mar;18(3):246-52
pubmed: 12603523